Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
APOA1	335	TRETINOIN	CHEMBL38		NCI	9392425
APOA1	335	RITONAVIR	CHEMBL163		PharmGKB
APOA1	335	APABETALONE	CHEMBL2393130		TdgClinicalTrial
APOA1	335	ALCOHOL	CHEMBL545		NCI	10956052
APOA1	335	FUROSEMIDE	CHEMBL35		NCI	1446618
APOA1	335	FENOFIBRATE	CHEMBL672		PharmGKB
APOA1	335	LAMIVUDINE	CHEMBL141		NCI	17538878
APOA1	335	GLUCAGON	CHEMBL266481		NCI	3130065
APOA1	335	TESTOSTERONE	CHEMBL386630		NCI	1764091

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
APOA1	rs670	CC	pravastatin	efficacy	no	as measured by increases in HDL-cholestrol. No significant association was seen between all three genotypes and response.	Genotype CC is not associated with response to pravastatin as compared to genotype TT.	16103896	982045927
APOA1	rs2727786	CG	fenofibrate	efficacy	yes	Response was measured as the percentage of triglyceride lowering. Please note that alleles have been complemented to the plus chromosomal strand.	Genotype CG is associated with decreased response to fenofibrate in people with Hypertriglyceridemia as compared to genotype CC.	19207029	769170846
APOA1	rs613808	AA + AG	fenofibrate	efficacy	no	No significant difference in the change in plasma triglyceride (TG) or high-density lipoprotein (HDL) levels between genotypes was seen, after three weeks of treatment with fenofibrate.	Genotypes AA + AG are not associated with response to fenofibrate in people with Hypertriglyceridemia as compared to genotype GG.	19057464	982038112
APOA1	rs670	CT + TT	fenofibrate	efficacy	no	No significant difference in the change in plasma triglyceride (TG) or high-density lipoprotein (HDL) levels between genotypes was seen, after three weeks of treatment with fenofibrate. Please note alleles have been complemented to the plus chromosomal strand.	Genotypes CT + TT are not associated with response to fenofibrate in people with Hypertriglyceridemia as compared to genotype CC.	19057464	982038105
APOA1	rs2727784	CC + CT	fenofibrate	efficacy	no	No significant difference in the change in plasma triglyceride (TG) or high-density lipoprotein (HDL) levels between genotypes was seen, after three weeks of treatment with fenofibrate. Please note alleles have been complemented to the plus chromosomal strand.	Genotypes CC + CT are not associated with response to fenofibrate in people with Hypertriglyceridemia as compared to genotype TT.	19057464	982038119
APOA1	rs11216158	AA + AG	fenofibrate	efficacy	no	No significant difference in the change in plasma triglyceride (TG) or high-density lipoprotein (HDL) levels between genotypes was seen, after three weeks of treatment with fenofibrate.	Genotypes AA + AG are not associated with response to fenofibrate in people with Hypertriglyceridemia as compared to genotype GG.	19057464	982038126
APOA1	rs964184	G	fenofibrate	efficacy	yes	Patients with the G allele had a greater increase in high-density lipoprotein (HDL) cholesterol and triglyceride (TG) level between baseline and either 3 weeks or 8 weeks of fenofibrate treatment, as compared to those with the C allele. Two cohorts were used: the discovery cohort came from the National Heart, Lung and Blood Institute GOLDN study population, and the replication cohort came from the Pharmacogenetics of Hypertriglyceridemia in Hispanics (HyperTG) study. Participants from the GOLDN study received fenofibrate treatment for 3 weeks, participants from HyperTG received it for 8 weeks. Differences in the discovery study population were significant after correction for multiple testing.	Allele G is associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to allele C.	23119086	982015058